ANAPC13

Across TCGA pan-cancer cohorts, ANAPC13 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ANAPC13 data layer compared with 23 for mass-spec protein.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher ANAPC13 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated ANAPC13 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and LUAD show a favorable association.

CCRCC, PDAC, and HNSC are the cancer types where ANAPC13 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	III,IV	0.904	0.105	.008	24	view →
PDAC	DFS	Tertile	III,IV	0.435	0.957	.024	16	view →
HNSC	DFS	Median	All	0.674	0.854	.008	8	view →
LUAD	OS	Tertile	II,III,IV	0.881	0.443	.018	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

ANAPC13–CCRCC (DFS)

Open the CCRCC breakdown →